Latest Posts
-
Pharma Talks – Interview with Alan Vanderborght, CEO and founder Kybora
16 December 2025 1. The M&A environment Jens: How would you describe the current state of pharma and biotech M&A? Are we returning to pre-2022 dynamics, or has something fundamentally shifted? Alan: The M&A landscape in biopharma is primarily driven by upcoming losses of exclusivity over the next five to ten years. Big pharma needs
-
Pharma Talks – Conversation with Frédéric Revah, CEO Genethon
13 November 2025 1. Progress of Genethon’s Gene Therapy Programs Q: How are Genethon’s programs progressing, especially in neuromuscular diseases? A: Genethon is currently advancing a robust pipeline of gene therapy programs with a strong focus on neuromuscular and metabolic disorders. One of the most significant recent achievements is the progression of the Duchenne muscular
-
Pharma Talks – Conversation with Udo Fichtner, Graf Lambsdorff & Compagnie: Transformation requires trust – and leadership that truly understands people
28.10.2025 1. Review & Context Jens Kurth:Leadership today isn’t defined by control, but by connection. Over the past years, organizations have been forced to reinvent how they lead and collaborate. What, in your view, has changed most in leadership? Udo Fichtner:Two trends are certainly dominant. The pandemic has made remote work popular, and technology –